Provider Alert! Prior Authorization Criteria to Change for Omalizumab (Xolair) Effective March 1, 2022
Date: March 3, 2022 Attention: Primary care providers Effective Date: March 01, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Effective on March 1, 2022, prior authorization criteria will change for omalizumab (Xolair) procedure code J2357. Prior authorization requests for clients with chronic idiopathic urticaria...
